{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T14:17:43Z","timestamp":1795184263280,"version":"4.10.3"},"reference-count":28,"publisher":"SLACK, Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background and Objective<\/jats:title>\n            <jats:p>While anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized treatment for diabetic macular edema, many patients still manifest refractory disease. This study evaluated rates of diabetic macular edema (DME) refractory to intravitreal bevacizumab in a diverse real-world setting, with the aim of studying demographic and optical coherence tomography (OCT)-based morphological factors associated with refractory disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This was a retrospective cohort study of patients receiving treatment. Refractory DME was defined as a gain in visual acuity of &lt; 5 letters after three consecutive injections of bevacizumab or less than 20% reduction in central retinal thickness (CRT) after three consecutive injections of bevacizumab. OCT images from preand post-injection visits were reviewed by two independent image readers. Multivariate logistic regression analysis evaluated for statistical significance between responders and those refractory to bevacizumab, and between Hispanic and non-Hispanic groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              Ninety-nine patients were included. Of the participants, 42% were Hispanic, 10% were reported as white, 11% were Asian, 11% were Black, and 26% were defined as \u201cnot reported.\u201d Fifty-four (54.5%) patients were refractory to bevacizumab and 45 were responders. Between responders and refractory patients, race was statistically significant (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = 0.04) with more refractory subjects found to be Hispanic (28\/54, 51.9%). OCT morphologic characteristics (CRT, number of hyperreflective foci, disorganization of inner retinal layers, ellipsoid zone discontinuity, and subretinal fluid) were not statistically significant between responders and refractory subjects. Multivariate logistic regression demonstrated an odds ratio of 5.7 for refractory disease for Hispanic patients (CI 1.687 to 19.445,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = 0.01). When comparing Hispanic to non-Hispanic patients, Hispanic patients had an average lower baseline visual acuity, lower CSTs, and higher HbA1C.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our study showed that Hispanic patients have a nearly 6 times relatively higher likelihood of refractory disease. There is a notable under-representation of these patients in completed clinical trials for diabetic retinopathy and DME.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic toggle=\"yes\">Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n                2025;56:346\u2013353.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/23258160-20250127-02","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:26:16Z","timestamp":1741965976000},"page":"346-353","source":"Crossref","is-referenced-by-count":1,"title":["Hispanic Ethnicity and Optical Coherence Tomography\u2013based Biomarkers as Predictive Factors of Diabetic Macular Edema Refractory to Bevacizumab"],"prefix":"10.3928","volume":"56","author":[{"given":"Erin","family":"Jennings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinah","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi","family":"Geevarghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Coulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasha","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.2854"},{"key":"e_1_3_1_3_2","volume-title":"National diabetes statistics report, 2020: estimates of diabetes and its burden in the United States","year":"2020","unstructured":"National diabetes statistics report, 2020: estimates of diabetes and its burden in the United States. Centers for Disease Control and Prevention. February 14, 2020. Accessed February 25, 2025. https:\/\/stacks.cdc.gov\/view\/cdc\/85309"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.11.014"},{"key":"e_1_3_1_5_2","unstructured":"Lucentis (ranibizumab injection) for intravitreal injection [package insert]. Genentech 2017. Accessed February 25 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125156s114lbl.pdf"},{"key":"e_1_3_1_6_2","unstructured":"EYLEA. Diabetic macular edema. Udated January 2024. Accessed Fenruary 25 2025. https:\/\/eylea.us\/s\/diabetic-macular-edema-dme"},{"key":"e_1_3_1_7_2","unstructured":"VABYSMO. VABYSMO (faricimab-svoa). Accessed September 27 2023. https:\/\/www.vabysmo.com\/dme\/howvabysmo-works.html"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.015"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2013.0832"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.393"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.01.031"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.039"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.06.017"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.02.036"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204225"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222364"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.11.008"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05148-6"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111841"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.021"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001070"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.031"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001626"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.047"},{"key":"e_1_3_1_26_2","volume-title":"Paper presented at: ASRS Annual Meeting","author":"Khan MA","unstructured":"Khan MA. Impact of race on vision outcomes in ranibizumab-treated patients with diabetic macular edema: a meta-analysis of 5 clinical trials. Paper presented at: ASRS Annual Meeting; October 9, 2021; San Antonio, TX."},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84553-7"},{"key":"e_1_3_1_28_2","unstructured":"National Eye Institute. Eye health data and statistics. Updated December 31 2024. Accessed February 25 2025. https:\/\/www.nei.nih.gov\/learn-about-eye-health\/resources-for-health-educators\/eye-health-data-and-statistics\/diabetic-retinopathy-data-and-statistics"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2021.12.016"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:43:25Z","timestamp":1750171405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20250127-02"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.3928\/23258160-20250127-02"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20250127-02","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}